We showed that SDT-mRNA can indeed be used for both purposes using known mutated antigens, including DHX40 and Melan-A/Mart-1 (A27L), and four HLA-A2-restricted candidate neoantigens that were identified in melanoma tumor sample using NGS and the ImmunoEngine pipeline developed by myNEO. This evidence concerns the gene DHX40 and melanoma.